Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0285351 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Torri D Metz und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Utah Health Hospitals and Clinics, Salt Lake City, UT, United States of America. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Importance Pregnancy induces unique physiologic changes to the immune response and hormonal changes leading to plausible differences in the risk of developing post-acute sequelae of SARS-CoV-2 (PASC), or Long COVID. Exposure to SARS-CoV-2 during pregnancy may also have long-term ramifications for exposed offspring, and it is critical to evaluate the health outcomes of exposed children. The National Institutes of Health (NIH) Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC aims to evaluate the long-term sequelae of SARS-CoV-2 infection in various populations. RECOVER-Pregnancy was designed specifically to address long-term outcomes in maternal-child dyads.
Methods
RECOVER-Pregnancy cohort is a combined prospective and retrospective cohort that proposes to enroll 2,300 individuals with a pregnancy during the COVID-19 pandemic and their offspring exposed and unexposed in utero, including single and multiple gestations. Enrollment will occur both in person at 27 sites through the Eunice Kennedy Shriver National Institutes of Health Maternal-Fetal Medicine Units Network and remotely through national recruitment by the study team at the University of California San Francisco (UCSF). Adults with and without SARS-CoV-2 infection during pregnancy are eligible for enrollment in the pregnancy cohort and will follow the protocol for RECOVER-Adult including validated screening tools, laboratory analyses and symptom questionnaires followed by more in-depth phenotyping of PASC on a subset of the overall cohort. Offspring exposed and unexposed in utero to SARS-CoV-2 maternal infection will undergo screening tests for neurodevelopment and other health outcomes at 12, 18, 24, 36 and 48 months of age. Blood specimens will be collected at 24 months of age for SARS-CoV-2 antibody testing, storage and anticipated later analyses proposed by RECOVER and other investigators.
Discussion
RECOVER-Pregnancy will address whether having SARS-CoV-2 during pregnancy modifies the risk factors, prevalence, and phenotype of PASC. The pregnancy cohort will also establish whether there are increased risks of adverse long-term outcomes among children exposed in utero. Clinical Trials.gov Identifier Clinical Trial Registration: http://www.clinicaltrials.gov . Unique identifier: NCT05172011 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, University of Utah Health Hospitals and Clinics, Salt Lake City, UT, United States of America.
- Biostatistics Center, The George Washington University, Washington, DC, United States of America.
- Department of Child and Adolescent Psychiatry, NYU Grossman School of Medicine, New York, NY, United States of America.
- Department of Pediatrics, New York University Grossman School of Medicine, New York, NY, United States of America.
- Department of Population Health, New York University Grossman School of Medicine, New York, NY, United States of America.
- Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA, United States of America.
ORCID-Profile: Torri D Metz, Richard Gallagher, Matthew K Hoffman, Beth A Plunkett, Grecio J Sandoval, Shannon M Schlater, Daniel W Skupski
Förderung
- NHLBI NIH HHS
- Foundation for the National Institutes of Health
Zitieren
APA
Metz, T. D., Clifton, R. G., Gallagher, R., Gross, R. S., Horwitz, L. I., Jacoby, V. L., Martin-Herz, S. P., Peralta-Carcelen, M., Reeder, H. T., Beamon, C. J., Chan, J., Chang, A. A., Costantine, M. M., Fitzgerald, M. L., Foulkes, A. S., Gibson, K. S., Güthe, N., Habli, M., Hackney, D. N., …, & RECOVER Initiative (2023). Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design. PLOS ONE. https://doi.org/10.1371/journal.pone.0285351
Vancouver
Metz TD, Clifton RG, Gallagher R, Gross RS, Horwitz LI, Jacoby VL, et al. Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design. PLOS ONE. 2023. doi:10.1371/journal.pone.0285351
BibTeX
@article{Metz2023,
author = {Metz, Torri D and Clifton, Rebecca G and Gallagher, Richard and Gross, Rachel S and Horwitz, Leora I and Jacoby, Vanessa L and Martin-Herz, Susanne P and Peralta-Carcelen, Myriam and Reeder, Harrison T and Beamon, Carmen J and Chan, James and Chang, A Ann and Costantine, Maged M and Fitzgerald, Megan L and Foulkes, Andrea S and Gibson, Kelly S and Güthe, Nick and Habli, Mounira and Hackney, David N and Hoffman, Matthew K and Hoffman, M Camille and Hughes, Brenna L and Katz, Stuart D and Laleau, Victoria and Mallett, Gail and Mendez-Figueroa, Hector and Monzon, Vanessa and Palatnik, Anna and Palomares, Kristy T S and Parry, Samuel and Pettker, Christian M and Plunkett, Beth A and Poppas, Athena and Reddy, Uma M and Rouse, Dwight J and Saade, George R and Sandoval, Grecio J and Schlater, Shannon M and Sciurba, Frank C and Simhan, Hyagriv N and Skupski, Daniel W and Sowles, Amber and Thaweethai, Tanayott and Thomas, Gelise L and Thorp, John M and Tita, Alan T and Weiner, Steven J and Weigand, Samantha and Yee, Lynn M and Flaherman, Valerie J and RECOVER Initiative, RECOVER Initiative},
title = {Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0285351}
}
EUVIMED